Who Optimizes SG&A Costs Better? AbbVie Inc. or Supernus Pharmaceuticals, Inc.

Optimizing SG&A Costs: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, AbbVie Inc. and Supernus Pharmaceuticals, Inc. have taken distinct paths in optimizing these costs. From 2014 to 2023, AbbVie Inc. saw a significant increase in SG&A expenses, peaking at approximately $15.3 billion in 2022, a 98% rise from 2014. In contrast, Supernus Pharmaceuticals, Inc. maintained a more modest growth, with expenses increasing by 364% over the same period, reaching around $377 million in 2022.

While AbbVie's larger scale and broader market presence contribute to its higher expenses, Supernus's leaner operations highlight its efficiency in cost management. This comparison underscores the diverse strategies companies employ to balance growth and operational efficiency in the ever-evolving pharmaceutical landscape.